- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03289871
Clinical Evaluation of the Efficacy of a Medical Device in Treatment of Toenail Onychomycosis
September 18, 2017 updated by: Oystershell NV
This study evaluates the effect of the medical device "Excilor® Fungal Nail Infection" in the treatment of toenail onychomycosis.
Half of the participants will receive the tested product and the other half will receive a comparator (Amorolfin 5%).
Patients will be followed during 6 months.
Study Overview
Study Type
Interventional
Enrollment (Actual)
112
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tunis, Tunisia
- Hospital Habib Thameur
-
Tunis, Tunisia
- Principal instruction military hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject having given her/his informed, written consent,
- Subject cooperative and aware of the modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.
- Subject being psychologically able to understand information and to give their/his/her consent.
- Age: more than 18 years.
- Subject with superficial onychomycosis on at least one great toenail or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement <2/3 of the tablet).
- Subject with positive results of KOH staining.
- Subject having stopped any systemic antifungal treatment since at least 6 months before inclusion and/or any topical antifungal treatment since at least 3 months before inclusion.
- Female subjects of childbearing potential should use an accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.
Exclusion Criteria:
- Subject considered by the Investigator likely to be non-compliant with the protocol.
- Patient enrolled in another clinical trial during the test period.
- Woman being pregnant, nursing or planning a pregnancy during the course of this study.
- Subject having a known allergy to one of the constituents of the tested products.
- Patient suffering from serious or progressive diseases (to investigator's discretion), such as diabetes, peripheral circulatory disease, HIV, psoriasis, lichen planus, immunosuppressive pathology….
- Subject with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis…).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Excilor
2 applications per day for 6 months
|
|
Active Comparator: Loceryl 5%
1 application per week for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
At the end of the study (day 168), evolution of the percentage of healthy surface versus baseline, was evaluated by a blinded investigator. Comparison with the comparator product.
Time Frame: After 168 days of treatment
|
Percentage healthy surface was assessed using digital image analysis.
Briefly, two macro-photographs (top and front) were made of the great toenail, placed beside a piece of graph paper to allow determination of the exact size of the nail during analysis (contour tracing).
Consequently, all pictures were digitalised and recorded on the computer.
Image analysis of the top picture was performed with Adobe Photoshop software.
For each photograph, a blinded dermatologist traced the healthy surface.
|
After 168 days of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
At different time points, evolution of the percentage of healthy surface versus baseline, was evaluated by a blinded investigator. Comparison with the comparator product.
Time Frame: After 14, 28, 56 and 112 days of treatment
|
Percentage healthy surface was assessed using digital image analysis.
Briefly, two macro-photographs (top and front) were made of the great toenail, placed beside a piece of graph paper to allow determination of the exact size of the nail during analysis (contour tracing).
Consequently, all pictures were digitalised and recorded on the computer.
Image analysis of the top picture was performed with Adobe Photoshop software.
For each photograph, a blinded dermatologist traced the healthy surface.
|
After 14, 28, 56 and 112 days of treatment
|
Evaluation of the clinical efficacy assessed by the investigator with structured scales. Comparison with the comparator product.
Time Frame: On Day 0, Day 14, Day 28, Day 56, Day 112 and Day 168
|
Onycholysis, nail dystrophy, nail discoloration and nail thickening were assessed using the following scores: 0 = none, 1 = very slight, 2 = slight, 3 =moderate, and 4 = severe. |
On Day 0, Day 14, Day 28, Day 56, Day 112 and Day 168
|
Evaluation of the microbiological efficacy of the product assessed by fungal culture and comparison with the comparator product.
Time Frame: On baseline (day zero) and day 168
|
On baseline (day zero) and day 168
|
|
Evaluation of the product tolerance, assessed by the investigator by clinical evaluation and subject interrogatory with a score from 0 (bad tolerance) to 3 (very good tolerance).
Time Frame: After 14, 28, 56 and 112 days of treatment
|
After 14, 28, 56 and 112 days of treatment
|
|
Evaluation of the quality of life of the subjects thanks to the questionnaire NailQoL . Comparison with the comparator product.
Time Frame: On Day 0, Day 14, Day 28, Day 56, Day 112 and Day 168
|
On Day 0, Day 14, Day 28, Day 56, Day 112 and Day 168
|
|
Subjective evaluation by subjects by completing the subjective evaluation questionnaire at each visit.
Time Frame: On Day 0, Day 14, Day 28, Day 56, Day 112 and Day 168
|
On Day 0, Day 14, Day 28, Day 56, Day 112 and Day 168
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Nejib Doss, MD, Principal Instruction military hospital of Tunis
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
May 3, 2016
First Submitted That Met QC Criteria
September 18, 2017
First Posted (Actual)
September 21, 2017
Study Record Updates
Last Update Posted (Actual)
September 21, 2017
Last Update Submitted That Met QC Criteria
September 18, 2017
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14E0752
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis
-
Vésale HospitalJanssen-Cilag Ltd.CompletedPrevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of OnychomycosisBelgium
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
Janssen Korea, Ltd., KoreaCompleted
-
ToeFX Inc.Active, not recruiting
-
SATO Pharmaceutical Co., Ltd.Active, not recruitingOnychomycosis of ToenailUnited States
-
Mahidol UniversityCompletedNon-dermatophyte OnychomycosisThailand
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Moberg Pharma ABCompletedDistal Subungual OnychomycosisUnited States, Canada
-
PfizerCompletedOnychomycosis of ToenailsUnited States, Canada
Clinical Trials on Excilor
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Oystershell NVEurofinsNot yet recruiting